FACIOSCAPULOHUMERAL DYSTROPHY
Clinical trials for FACIOSCAPULOHUMERAL DYSTROPHY explained in plain language.
Never miss a new study
Get alerted when new FACIOSCAPULOHUMERAL DYSTROPHY trials appear
Sign up with your email to follow new studies for FACIOSCAPULOHUMERAL DYSTROPHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for FSHD: phase 3 trial of AOC 1020 begins
Disease control Recruiting nowThis study tests an experimental drug called AOC 1020 for facioscapulohumeral muscular dystrophy (FSHD), a genetic condition that causes progressive muscle weakness. About 200 adults with a confirmed FSHD diagnosis who can still walk will receive either the drug or a placebo by I…
Matched conditions: FACIOSCAPULOHUMERAL DYSTROPHY
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 26, 2026 03:35 UTC
-
New study aims to simplify walking assessments for rare muscle disease
Knowledge-focused Recruiting nowThis study looks at whether quick, easy walking tests can effectively measure mobility problems in adults with facioscapulohumeral muscular dystrophy (FSH), a genetic muscle disease that often causes walking difficulties. Researchers will compare these simple tests with the stand…
Matched conditions: FACIOSCAPULOHUMERAL DYSTROPHY
Phase: NA • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated May 18, 2026 12:00 UTC